Quantum BioPharma’s LUCID-MS Completes Phase 1, IND Filing in April 2026
QNTM•Quantum BioPharma’s LUCID-MS completed Phase 1 trials in healthy volunteers, demonstrating a favorable safety profile and good tolerability. The company submitted an Investigational New Drug application for LUCID-MS to the FDA in April 2026.
1. LUCID-MS Program Overview
Quantum BioPharma’s LUCID-MS candidate targets demyelination by promoting myelin repair and providing neuroprotection in multiple sclerosis patients.
2. Phase 1 Safety Results
The company completed Phase 1 clinical studies in healthy volunteers, reporting a favorable safety profile and good tolerability without serious adverse events.
3. IND Submission in April 2026
In April 2026, Quantum BioPharma submitted an Investigational New Drug application to the FDA, marking a key regulatory milestone toward evaluating LUCID-MS in patients with multiple sclerosis.
4. Next Steps and Outlook
Pending FDA acceptance, Phase 2 efficacy trials are expected later in 2026 to evaluate therapeutic benefit in patients with active demyelination.
